Cited by 219Hepatitis B Virus StudiesHepatitis C virus researchLiver physiology and pathology

The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.

Intrahepatic Hepatitis B Virus Covalently Closed Circular DNA Can Be a Predictor of Sustained Response to Therapy

Open access

Sung, Joseph J.Y., Wong, May-Ling, Bowden, Scott, Liew, Choong-Tsek, Hui, Alex Y., Wong, Vincent W.S., Leung, Nancy W.Y., Locarnini, Stephen, Chan, Henry L.Y.·2005·Gastroenterology

DOI 10.1053/j.gastro.2005.03.009

Open this paper in CoChat — free account Open PDF

Abstract

Background & aims This study aimed to determine whether intrahepatic hepatitis B virus (HBV) covalently closed circular (ccc) DNA and total HBV DNA levels at the end of therapy would predict sustained response to therapy.Methods Hepatitis B e antigen (HBeAg)-positive chronic hepatitis B patients receiving either lamivudine monotherapy or combination of peginterferon and lamivudine had liver biopsy at the end of 1 year therapy and were followed for 52 more weeks after cessation of therapy. Serum HBV DNA, intrahepatic HBV ccc DNA, and total HBV DNA levels were determined.Results Forty-seven patients, including 34 males and 13 females, were studied. Twenty-seven patients received combination therapy, and 20 patients received lamivudine monotherapy. Twenty-nine patients had end-of-treatment virologic response, and 15 patients had sustained response 52 weeks after therapy. At the end of treatment, log serum HBV DNA levels correlated well with log intrahepatic HBV cccDNA and log intrahepatic total HBV DNA levels. Log intrahepatic cccDNA and log intrahepatic total DNA levels were significantly lower among patients with sustained virologic response. The adjusted odds ratio for log cccDNA was 5.3 (95% CI: 1.5-18.2, P = .009) and, for log intrahepatic HBV DNA, was 4.4 (95% CI: 1.3-14.7, P = .015) to predict sustained virologic response. Using log cccDNA at -0.80 copies/genome equivalent as cutoff, the sensitivity, specificity, and positive and negative predictive values and accuracy of predicting sustained virologic response were 73%, 78%, 56%, 86%, and 77% respectively.Conclusions Intrahepatic HBV cccDNA and intrahepatic total HBV DNA levels at the end of therapy are superior to serum HBV DNA as surrogates of sustained virologic response.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1053/j.gastro.2005.03.009

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Chronic hepatitis B
Lok, A. S.-F., & McMahon, B. J. (2007) · Hepatology · doi:10.1002/hep.21513 · Cited by 3,092
Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy1 ☆
Werle–Lapostolle, B., Bowden, S., Locarnini, S., Wursthorn, K., Petersen, J., Lau, G., Trepo, C., Marcellin, P., Goodman, Z., & Delaney IV, W. E. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.03.018 · Cited by 905
Chronic hepatitis B
Lok, A. S. F., & McMahon, B. J. (2001) · Hepatology · doi:10.1053/jhep.2001.29401 · Cited by 711
Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B
Liaw, Y., Leung, N. W. Y., Chang, T., Guan, R., Tai, D., Ng, K., Chien, R., Dent, J. C., Roman, L., Edmundson, S., et al. (2000) · Gastroenterology · doi:10.1053/gast.2000.8559 · Cited by 687
Formation of the pool of covalently closed circular viral DNA in hepadnavirus-infected cells
Tuttleman, J. S., Pourcel, C., & Summers, J. W. (1986) · Cell · doi:10.1016/0092-8674(86)90602-1 · Cited by 672
Prevalence and Clinical Correlates of YMDD Variants during Lamivudine Therapy for Patients with Chronic Hepatitis B
Lai, C., Dienstag, J. L., Schiff, E. R., Leung, N. W. Y., Atkins, M., Hunt, C. M., Brown, N. A., Woessner, M. A., Boehme, R. E., & Condreay, L. D. (2003) · Clinical Infectious Diseases · doi:10.1086/368083 · Cited by 633
Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase
Angus, P., Vaughan, R., Xiong, S., Yang, H., Delaney, W. E., Gibbs, C. S., Brosgart, C. L., Colledge, D., Edwards, R., Ayres, A., et al. (2003) · Gastroenterology · doi:10.1016/s0016-5085(03)00939-9 · Cited by 563
Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region
Stuyver, L. J. (2001) · Hepatology · doi:10.1053/jhep.2001.22166 · Cited by 384
Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea
Song, B.-C., Suh, D. J., Lee, H. C., Chung, Y., & Lee, Y. S. (2000) · Hepatology · doi:10.1053/jhep.2000.16665 · Cited by 335
The covalently closed duplex form of the hepadnavirus genome exists in situ as a heterogeneous population of viral minichromosomes
Newbold, J. E., Xin, H., Tencza, M. G., Sherman, G., Dean, J., Bowden, S., & LOCARNINI, S. A. (1995) · Journal of Virology · doi:10.1128/jvi.69.6.3350-3357.1995 · Cited by 313

Show all 32 references

Sorted by citations

Hepatitis B Virus Resistance to Nucleos(t)ide Analogues
Zoulim, F., & LOCARNINI, S. A. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.08.063 · Cited by 724
Silver Nanoparticles Inhibit Hepatitis B virus Replication
Lu, L., Sun, R. W., Chen, R., Hui, C., Ho, C., Luk, J. M., Lau, G. K. K., & Che, C. (2008) · Antiviral Therapy · doi:10.1177/135965350801300210 · Cited by 605
Hepatitis B Reactivation Associated With Immune Suppressive and Biological Modifier Therapies: Current Concepts, Management Strategies, and Future Directions
Loomba, R. S., & Liang, T. J. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.02.009 · Cited by 619
Control of cccDNA function in hepatitis B virus infection
Levrero, M., Pollicino, T., Petersen, J., Belloni, L., Raimondo, G., & Dandri, M. (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2009.05.022 · Cited by 552
Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B
Wursthorn, K., Lütgehetmann, M., Dandri, M., Volz, T., Buggisch, P., Zöllner, B., Longerich, T., Schirmacher, P., Metzler, F., Zankel, M., et al. (2006) · Hepatology · doi:10.1002/hep.21282 · Cited by 437
The CRISPR/Cas9 system facilitates clearance of the intrahepatic HBV templates in vivo
Lin, S.-R., Yang, H.-C., Kuo, Y.-T., Liu, C.-J., Yang, T.-Y., Sung, K.-C., Lin, Y.-Y., Wang, H.-Y., Wang, C.-C., Shen, Y.-C., et al. (2014) · Molecular Therapy - Nucleic Acids · doi:10.1038/mtna.2014.38 · Cited by 386
Serum Hepatitis B Surface Antigen Quantitation Can Reflect Hepatitis B Virus in the Liver and Predict Treatment Response
Chan, H. L., Wong, V. W., Tse, A. M. L., Tse, C., Chim, A. M., Chan, H., Wong, G. L., & Sung, J. J. �. (2007) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2007.09.005 · Cited by 350
Present and future therapies of hepatitis B: From discovery to cure
Liang, T. J., Block, T. M., McMahon, B. J., Ghany, M. G., Urban, S., Guo, J., LOCARNINI, S. A., Zoulim, F., Chang, K., & Lok, A. S.-F. (2015) · Hepatology · doi:10.1002/hep.28025 · Cited by 322
Prediction of Sustained Response to Peginterferon Alfa-2b for Hepatitis B e Antigen–Positive Chronic Hepatitis B Using on-Treatment Hepatitis B Surface Antigen Decline
Sonneveld, M. J., Rijckborst, V., Boucher, C. A., Hansen, B. E., & Janssen, H. L. A. (2010) · Hepatology · doi:10.1002/hep.23844 · Cited by 293
Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy
van Bömmel, F., Zöllner, B., Sarrazin, C., Spengler, U., Hüppe, D., Möller, B., Feucht, H., Wiedenmann, B. J., & Berg, T. (2006) · Hepatology · doi:10.1002/hep.21253 · Cited by 286
Hepatitis B virus genetic variability and evolution
Kay, A., & Zoulim, F. (2007) · Virus Research · doi:10.1016/j.virusres.2007.02.021 · Cited by 278
Host-Directed Antiviral Therapy
Kumar, N., Sharma, S., Kumar, R., Tripathi, B. N., Barua, S., Ly, H., & Rouse, B. T. (2020) · Clinical Microbiology Reviews · doi:10.1128/cmr.00168-19 · Cited by 289
A Longitudinal Study on the Natural History of Serum Hepatitis B Surface Antigen Changes in Chronic Hepatitis B
Chan, H. L., Wong, V. W., Wong, G. L., Tse, C., Chan, H., & Sung, J. J. �. (2010) · Hepatology · doi:10.1002/hep.23803 · Cited by 253
Benefits and risks of interferon therapy for hepatitis B #
Perrillo, R. (2009) · Hepatology · doi:10.1002/hep.22956 · Cited by 237
New insight in the pathobiology of hepatitis B virus infection
Dandri, M., & LOCARNINI, S. A. (2012) · Gut · doi:10.1136/gutjnl-2012-302056 · Cited by 232
Virologic Monitoring of Hepatitis B Virus Therapy in Clinical Trials and Practice: Recommendations for a Standardized Approach
Pawlotsky, J., Dusheiko, G. M., Hatzakis, A. E., Lau, D., Lau, G. K. K., Liang, T. J., LOCARNINI, S. A., Martin, P. B., Richman, D. D., & Zoulim, F. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.11.036 · Cited by 228
Hepatitis B in China
Liu, J., & Fan, D. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60723-5 · Cited by 227
Epigenetic regulation of hepatitis B virus covalently closed circular DNA: Implications for epigenetic therapy against chronic hepatitis B
Hong, X., Kim, E. S., & Guo, H. (2017) · Hepatology · doi:10.1002/hep.29479 · Cited by 211
Formation of Hepatitis B Virus Covalently Closed Circular DNA: Removal of Genome-Linked Protein
Gao, W., & Hu, J. (2007) · Journal of Virology · doi:10.1128/jvi.02721-06 · Cited by 203
The Role of cccDNA in HBV Maintenance
Allweiss, L., & Dandri, M. (2017) · Viruses · doi:10.3390/v9060156 · Cited by 203
Therapeutic strategies in the management of patients with chronic hepatitis B virus infection
Papatheodoridis, G., Manolakopoulos, S., Dusheiko, G. M., & Archimandritis, A. J. (2007) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(07)70264-5 · Cited by 201
Intrahepatic levels and replicative activity of covalently closed circular hepatitis B virus DNA in chronically infected patients
Laras, A., Koskinas, J. S., Dimou, E., Kostamena, A., & Hadziyannis, S. J. (2006) · Hepatology · doi:10.1002/hep.21299 · Cited by 194
Impaired Intrahepatic Hepatitis B Virus Productivity Contributes to Low Viremia in Most HBeAg-Negative Patients
Volz, T., Lütgehetmann, M., Wachtler, P., Jacob, A., Quaas, A., Murray, J. M., Dandri, M., & Petersen, J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.06.057 · Cited by 194
Correlation between serum hepatitis B virus core‐related antigen and intrahepatic covalently closed circular DNA in chronic hepatitis B patients
Suzuki, F., Miyakoshi, H., Kobayashi, M., & Kumada, H. (2008) · Journal of Medical Virology · doi:10.1002/jmv.21339 · Cited by 182
Hepatitis B: Reflections on the current approach to antiviral therapy
Zoulim, F., & Perrillo, R. (2008) · Journal of Hepatology · doi:10.1016/j.jhep.2008.01.011 · Cited by 166
Diagnosis of hepatitis B virus infection through serological and virological markers
Kao, J. (2008) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/17474124.2.4.553 · Cited by 159
An efficient antiviral strategy for targeting hepatitis B virus genome using transcription activator-like effector nucleases
Chen, J., Zhang, W., Lin, J., Wang, F., Wu, M., Chen, C., Zheng, Y., Peng, X., Li, J., & Yuan, Z. (2014) · Molecular Therapy · doi:10.1038/mt.2013.212 · Cited by 159
Prediction of Treatment-Related HBsAg Loss in HBeAg-Negative Chronic Hepatitis B: A Clue from Serum HBsAg Levels
Manesis, E. K., Hadziyannis, E. S., Angelopoulou, O. P., & Hadziyannis, S. J. (2007) · Antiviral Therapy · doi:10.1177/135965350701200107 · Cited by 157
Molecular Testing in the Diagnosis and Management of Chronic Hepatitis B
Valsamakis, A. (2007) · Clinical Microbiology Reviews · doi:10.1128/cmr.00009-07 · Cited by 154
Metabolism and function of hepatitis B virus cccDNA: Implications for the development of cccDNA-targeting antiviral therapeutics
Guo, J., & Guo, H. (2015) · Antiviral Research · doi:10.1016/j.antiviral.2015.08.005 · Cited by 153
Kinetics of hepatitis B surface antigen differ between treatment with peginterferon and entecavir
Reijnders, J. G. P., Rijckborst, V., Sonneveld, M. J., Scherbeijn, S. M. J., Boucher, C. A., Hansen, B. E., & Janssen, H. L. A. (2010) · Journal of Hepatology · doi:10.1016/j.jhep.2010.07.046 · Cited by 148
Persistence of hepatitis B virus covalently closed circular DNA in hepatocytes: molecular mechanisms and clinical significance
Yang, H., & Kao, J. (2014) · Emerging Microbes & Infections · doi:10.1038/emi.2014.64 · Cited by 142
The Role of Hepatitis B Surface Antigen in Nucleos(t)ide Analogues Cessation Among Asian Patients With Chronic Hepatitis B: A Systematic Review
Liu, J., Li, T., Zhang, L., & Xu, A. (2018) · Hepatology · doi:10.1002/hep.30474 · Cited by 136
Chronic hepatitis B: What should be the goal for new therapies?
Block, T. M., Gish, R. G., Guo, H., Mehta, A. S., Cuconati, A., London, W. T., & Guo, J. (2013) · Antiviral Research · doi:10.1016/j.antiviral.2013.01.006 · Cited by 129
Entecavir plus tenofovir combination as rescue therapy in pre-treated chronic hepatitis B patients: An international multicenter cohort study
Petersen, J., Ratziu, V., Buti, M., Janssen, H. L. A., Brown, A. S., Lampertico, P., Schollmeyer, J., Zoulim, F., Wedemeyer, H. H., Sterneck, M. R., et al. (2011) · Journal of Hepatology · doi:10.1016/j.jhep.2011.09.018 · Cited by 122
Dual gRNAs guided CRISPR/Cas9 system inhibits hepatitis B virus replication
Wang, J. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i32.9554 · Cited by 117
Use of tumor necrosis factor α inhibitors in hepatitis B surface antigen-positive patients: a literature review and potential mechanisms of action
Carroll, M. B., & Forgione, M. A. (2010) · Clinical Rheumatology · doi:10.1007/s10067-010-1523-2 · Cited by 116
Decay of ccc-DNA marks persistence of intrahepatic viral DNA synthesis under tenofovir in HIV-HBV co-infected patients
Boyd, A. C., Lacombe, K., Lavocat, F., Maylin, S., Miailhes, P., Lascoux‐Combe, C., Delaugerre, C., Girard, P., & Zoulim, F. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.05.014 · Cited by 114
Prediction of off-Treatment Response to Lamivudine by Serum Hepatitis B Surface Antigen Quantification in Hepatitis B E Antigen-Negative Patients
Chan, H. L., Wong, G. L., Chim, A. M.-L., Chan, H.-Y., Chu, S. H.-T., & Wong, V. W. (2011) · Antiviral Therapy · doi:10.3851/imp1921 · Cited by 109
Hepatitis B virus e antigen production is dependent upon covalently closed circular (ccc) DNA in HepAD38 cell cultures and may serve as a cccDNA surrogate in antiviral screening assays
Zhou, T., Guo, H., Guo, J., Cuconati, A., Mehta, A. S., & Block, T. M. (2006) · Antiviral Research · doi:10.1016/j.antiviral.2006.05.006 · Cited by 109
Lipid nanoparticles loaded with ribonucleoprotein–oligonucleotide complexes synthesized using a microfluidic device exhibit robust genome editing and hepatitis B virus inhibition
Suzuki, Y., Onuma, H., Sato, R., Sato, Y., Hashiba, A., Maeki, M., Tokeshi, M., Kayesh, M. E. H., Kohara, M., Tsukiyama–Kohara, K., et al. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.12.013 · Cited by 102
Immune cell responses are not required to induce substantial hepatitis B virus antigen decline during pegylated interferon-alpha administration
Allweiss, L., Volz, T., Lütgehetmann, M., Giersch, K., Bornscheuer, T., Lohse, A. W., Petersen, J., Ma, H., Klumpp, K., Fletcher, S. P., et al. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2013.10.021 · Cited by 91
Serum Hepatitis B Virus DNA, RNA, and HBsAg: Which Correlated Better with Intrahepatic Covalently Closed Circular DNA before and after Nucleos(t)ide Analogue Treatment?
Gao, Y., Li, Y., Meng, Q., Zhang, Z., Zhao, P., Shang, Q., Li, Y., Su, M., Li, T., Liu, X., et al. (2017) · Journal of Clinical Microbiology · doi:10.1128/jcm.00760-17 · Cited by 86
Two-year Lamivudine treatment for Hepatitis B e Antigen-Negative Chronic Hepatitis B: A Double-Blind, Placebo-Controlled Trial
Chan, H. L., Wang, H., Niu, J., Chim, A. M., & Sung, J. J. �. (2007) · Antiviral Therapy · doi:10.1177/135965350701200308 · Cited by 85
Roadmap to functional cure of chronic hepatitis B: An expert consensus
Ning, Q., Wu, D., Wang, G., Ren, H., Gao, Z., Hu, P., Han, M., Wang, Y., Zhang, W., Lu, F., et al. (2019) · Journal of Viral Hepatitis · doi:10.1111/jvh.13126 · Cited by 93
Serum hepatitis B core‐related antigen as a treatment predictor of pegylated interferon in patients with HB eAg‐positive chronic hepatitis B
Chuaypen, N., Posuwan, N., Payungporn, S., Tanaka, Y., Shinkai, N., Poovorawan, Y., & Tangkijvanich, P. (2015) · Liver International · doi:10.1111/liv.13046 · Cited by 81
Aiming for cure in HBV and HDV infection
Petersen, J., Thompson, A. J. V., & Levrero, M. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.05.043 · Cited by 80
Cellular DNA Topoisomerases Are Required for the Synthesis of Hepatitis B Virus Covalently Closed Circular DNA
Sheraz, M., Cheng, J.-J., Tang, L., Chang, J.-H., & Guo, J.-T. (2019) · Journal of Virology · doi:10.1128/jvi.02230-18 · Cited by 66
Hepatitis B virus RNA is measurable in serum and can be a new marker for monitoring lamivudine therapy
Rokuhara, A., Matsumoto, A., Tanaka, E., Umemura, T., Yoshizawa, K., Kimura, T., Maki, N., & Kiyosawa, K. (2006) · Journal of Gastroenterology · doi:10.1007/s00535-006-1856-4 · Cited by 76
Quantification of serum hepatitis B surface antigen: is it useful for the management of chronic hepatitis B?
Janssen, H. L. A., Sonneveld, M. J., & Brunetto, M. R. (2011) · Gut · doi:10.1136/gutjnl-2011-301096 · Cited by 75
Durable Hepatitis B Surface Antigen Decline in Hepatitis B E Antigen-Positive Chronic Hepatitis B Patients Treated with Pegylated Interferon-α2B: Relation to Response and HBV Genotype
Sonneveld, M. J., Rijckborst, V., Çakaloğlu, Y., Simon, K. A., Heathcote, E. J., Tabak, F., Mach, T., Boucher, C. A., Hansen, B. E., Zeuzem, S., et al. (2011) · Antiviral Therapy · doi:10.3851/imp1887 · Cited by 71
Presence of intrahepatic (total and ccc) HBV DNA is not predictive of HBV recurrence after liver transplantation
Hussain, M., Soldevila‐Pico, C., Emre, S., Luketic, V. A., Lok, A. S.-F., & NIH HBV-OLT Study Group (2007) · Liver Transplantation · doi:10.1002/lt.21179 · Cited by 71
Monitoring during and after antiviral therapy for hepatitis B #
Andersson, K. L., & Chung, R. T. (2009) · Hepatology · doi:10.1002/hep.22899 · Cited by 69
Antiviral therapy of chronic hepatitis B
Zoulim, F. (2006) · Antiviral Research · doi:10.1016/j.antiviral.2006.04.003 · Cited by 69
Sequential Combination Therapy Leads to Biochemical and Histological Improvement Despite Low Ongoing Intrahepatic Hepatitis B virus Replication
Lütgehetmann, M., Volz, T., Quaas, A., Zankel, M., Fischer, C., Dandri, M., & Petersen, J. (2008) · Antiviral Therapy · doi:10.1177/135965350801300106 · Cited by 68
CRISPR/Cas9 produces anti-hepatitis B virus effect in hepatoma cells and transgenic mouse
Zhu, W., Xie, K., Xu, Y., Wang, L., Chen, K., Zhang, L., & Fang, J. (2016) · Virus Research · doi:10.1016/j.virusres.2016.04.003 · Cited by 66
The current status and future directions of hepatitis B antiviral drug discovery
Tang, L., Zhao, Q., Wu, S., Cheng, J., Chang, J., & Guo, J. (2016) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2017.1255195 · Cited by 65
Hepatitis B virus: From diagnosis to treatment
Dény, P., & Zoulim, F. (2010) · Pathologie Biologie · doi:10.1016/j.patbio.2010.05.002 · Cited by 64
Serum HBV RNA is a predictor of early emergence of the YMDD mutant in patients treated with lamivudine†
Hatakeyama, T., Noguchi, C., Hiraga, N., Mori, N., Tsuge, M., Imamura, M., Takahashi, S., Kawakami, Y., Fujimoto, Y., Ochi, H., et al. (2007) · Hepatology · doi:10.1002/hep.21581 · Cited by 64
Serum HB crAg is better than HBV RNA and HB sAg in reflecting intrahepatic covalently closed circular DNA
Chen, E., Wang, M.-L., Tao, Y., Wu, D., Liao, J., He, M., & Tang, H. (2019) · Journal of Viral Hepatitis · doi:10.1111/jvh.13061 · Cited by 63
Relationship between serum hepatitis B virus DNA and surface antigen with covalently closed circular DNA in HBeAg‐negative patients
Lin, L. Y., Wong, V. W., Zhou, H., Chan, H., Gui, H., Guo, S., Wang, H., Huang, L., Bao, S., Xie, Q., et al. (2010) · Journal of Medical Virology · doi:10.1002/jmv.21863 · Cited by 63
Detection of HBV Covalently Closed Circular DNA
Li, X., Zhao, J., Yuan, Q., & Xia, N. (2017) · Viruses · doi:10.3390/v9060139 · Cited by 60
Combination of hepatitis B viral antigens and DNA for prediction of relapse after discontinuation of nucleos(t)ide analogs in patients with chronic hepatitis B
Matsumoto, A., Tanaka, E., Suzuki, Y., Kobayashi, M., Tanaka, Y., Shinkai, N., Hige, S., Yatsuhashi, H., Nagaoka, S., Chayama, K., et al. (2011) · Hepatology Research · doi:10.1111/j.1872-034x.2011.00910.x · Cited by 58
The role of quantitative hepatitis B serology in the natural history and management of chronic hepatitis B
Nguyen, T., Desmond, P. V., & LOCARNINI, S. A. (2009) · Hepatology International · doi:10.1007/s12072-009-9149-7 · Cited by 56
Quantitative analysis of HBV cccDNA from clinical specimens: correlation with clinical and virological response during antiviral therapy
Bourne, E. J., Dienstag, J. L., Lopez, V. A., Sander, T. J., Longlet, J. M., Hall, J. G., Kwiatkowski, R. W., Wright, T. L., Lai, C., & Condreay, L. D. (2006) · Journal of Viral Hepatitis · doi:10.1111/j.1365-2893.2006.00775.x · Cited by 54
Therapy of Hepatitis B — Viral Suppression or Eradication?
Perrillo, R. P. (2006) · Hepatology · doi:10.1002/hep.20970 · Cited by 54
Strategies to Eliminate HBV Infection
Kapoor, R., & Kottilil, S. (2014) · Future Virology · doi:10.2217/fvl.14.36 · Cited by 55
Low pretreatment serum HBsAg level and viral mutations as predictors of response to PEG-interferon alpha-2b therapy in chronic hepatitis B
Tangkijvanich, P., Komolmit, P., Mahachai, V., Sa‐nguanmoo, P., Theamboonlers, A., & Poovorawan, Y. (2009) · Journal of Clinical Virology · doi:10.1016/j.jcv.2009.07.005 · Cited by 52
Mechanism of Hepatitis B Virus Persistence in Hepatocytes and Its Carcinogenic Potential
Dandri, M., & Petersen, J. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw023 · Cited by 52
Chronic hepatitis B: peginterferon or nucleos(t)ide analogues?
Sonneveld, M. J., & Janssen, H. L. A. (2011) · Liver International · doi:10.1111/j.1478-3231.2010.02384.x · Cited by 50
Effect of oxymatrine on the replication cycle of hepatitis B virusin vitro
Xu, W. (2010) · World Journal of Gastroenterology · doi:10.3748/wjg.v16.i16.2028 · Cited by 50
Occult hepatitis B virus infection of donor and recipient origin after liver transplantation despite nucleoside analogue prophylaxis
Cheung, C. K. Y., Lo, C. M., Man, K., & Lau, G. K. K. (2010) · Liver Transplantation · doi:10.1002/lt.22169 · Cited by 49
Clinical relevance of the study of hepatitis B virus covalently closed circular DNA
Kumar, R., Pérez‐del‐Pulgar, S., Testoni, B., Lebossé, F., & Zoulim, F. (2016) · Liver International · doi:10.1111/liv.13001 · Cited by 48
Kinetics of serum HBsAg and intrahepatic cccDNA during pegylated interferon therapy in patients with HBeAg‐positive and HBeAg‐negative chronic hepatitis B
Chuaypen, N., Sriprapun, M., Praianantathavorn, K., Payungporn, S., Wisedopas, N., Poovorawan, Y., & Tangkijvanich, P. (2016) · Journal of Medical Virology · doi:10.1002/jmv.24601 · Cited by 46
Synthesis of sulfamoylbenzamide derivatives as HBV capsid assembly effector
Sari, O., Bouclé, S., Cox, B. D., Ozturk, T. T., Russell, O. O., Bassit, L., Amblard, F., & Schinazi, R. F. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.06.062 · Cited by 45
cccDNA Maintenance in Chronic Hepatitis B – Targeting the Matrix of Viral Replication
Dandri, M., & Petersen, J. (2020) · Infection and Drug Resistance · doi:10.2147/idr.s240472 · Cited by 43
Change in Serum Hepatitis B Surface Antigen Level and Its Clinical Significance in Treatment-naïve, Hepatitis B e Antigen-positive Patients Receiving Entecavir
Jung, Y. K., Kim, J. H., Lee, Y., Lee, H. J., Yoon, E. L., Jung, E. S., Hong, S. K., Joo, M. K., Yeon, J. E., Park, J. J., et al. (2010) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0b013e3181d52946 · Cited by 42
Predictors of Treatment Response in Chronic Hepatitis B
Wong, G. L., & Chan, H. L. (2009) · Drugs · doi:10.2165/11319850-000000000-00000 · Cited by 42
Antiviral Therapy of Chronic Hepatitis B: Prevention of Drug Resistance
Fournier, C., & Zoulim, F. (2007) · Clinics in Liver Disease · doi:10.1016/j.cld.2007.08.013 · Cited by 42
Comparison between quantitative hepatitis B surface antigen, hepatitis B e‐antigen and hepatitis B virus DNA levels for predicting virological response to pegylated interferon‐α‐2b therapy in hepatitis B e‐antigen‐positive chronic hepatitis B
Tangkijvanich, P., Komolmit, P., Mahachai, V., Sa‐nguanmoo, P., Theamboonlers, A., & Poovorawan, Y. (2010) · Hepatology Research · doi:10.1111/j.1872-034x.2009.00592.x · Cited by 41
Quantitation of HBV covalently closed circular DNA in micro formalin fixed paraffin-embedded liver tissue using rolling circle amplification in combination with real-time PCR
Zhong, Y., Han, J., Zou, Z., Liu, S., Tang, B., Xiaoqiang, R., Li, X., Zhao, Y., Liu, Y., Zhou, D., et al. (2011) · Clinica Chimica Acta · doi:10.1016/j.cca.2011.06.031 · Cited by 41
Early serum HBsAg level as a strong predictor of sustained response to peginterferon alfa‐2a in HBeAg ‐negative chronic hepatitis B
Peng, C. ‐., Lai, H., Li, Y., Su, W., Chuang, P., & Kao, J. ‐. (2012) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2011.04973.x · Cited by 40
Control of hepatitis B virus replication by interferons and Toll-like receptor signaling pathways
Pei, R. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i33.11618 · Cited by 41
Correlation of HBcrAg with Intrahepatic Hepatitis B Virus Total DNA and Covalently Closed Circular DNA in HBeAg-Positive Chronic Hepatitis B Patients
Wang, L., Cao, X., Wang, Z.-Z., Gao, Y., Deng, J., Liu, X., & Zhuang, H. (2018) · Journal of Clinical Microbiology · doi:10.1128/jcm.01303-18 · Cited by 40
Intrahepatic response markers in chronic hepatitis B patients treated with peginterferon alpha‐2a and adefovir
Takkenberg, R. B., Terpstra, V., Zaaijer, H. L., Weegink, C. J., Dijkgraaf, M. G. W., Jansen, P. L. M., Beld, M., & Reesink, H. W. (2011) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2011.06766.x · Cited by 39
Recent data on treatment of chronic hepatitis B with nucleos(t)ide analogues
Leung, N. W. Y. (2008) · Hepatology International · doi:10.1007/s12072-008-9061-6 · Cited by 39
Integration of hepatitis B virus S gene impacts on hepatitis B surface antigen levels in patients with antiviral therapy
Hu, B., Wang, R., Fu, J., Su, M., Du, M., Liu, Y., Li, H., Wang, H., Lu, F., & Jiang, J. (2017) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.14075 · Cited by 39
Serum HBV core‐related antigen is a good predictor for spontaneous HBeAg seroconversion in chronic hepatitis B patients
Song, G., Yang, R., Rao, H., Feng, B., Ma, H., Jin, Q., & Wei, L. (2016) · Journal of Medical Virology · doi:10.1002/jmv.24657 · Cited by 38
Total and covalently closed circular DNA detection in liver tissue of long-term survivors transplanted for HBV-related cirrhosis
Lenci, I., Marcuccilli, F., Tisone, G., Paolo, D. D., Tariciotti, L., Ciotti, M., Guenci, T., Perno, C. F., & Angelico, M. (2010) · Digestive and Liver Disease · doi:10.1016/j.dld.2009.12.003 · Cited by 37
Serum HBV RNA correlated with intrahepatic cccDNA more strongly than other HBV markers during peg-interferon treatment
Wang, X., Chi, X., Wu, R., Xu, H., Gao, X., Yu, L., Liu, L., Zhang, M., Tan, Y., Niu, J., et al. (2021) · Virology Journal · doi:10.1186/s12985-020-01471-2 · Cited by 36
Predictive value of HBsAg quantification for determining the clinical course of genotype C HBeAg ‐negative carriers
Park, H., Lee, J. M., Seo, J. H., Kim, H. S., Ahn, S. H., Kim, D. Y., Han, K., Chon, C. Y., & Park, J. Y. (2011) · Liver International · doi:10.1111/j.1478-3231.2011.02693.x · Cited by 35
Analysis of Hepatitis B Virus Intrahepatic Covalently Closed Circular DNA and Serum Viral Markers in Treatment-Naive Patients with Acute and Chronic HBV Infection
Li, W., Zhao, J., Zou, Z., Liu, Y., Li, B., Sun, Y. H., Li, X., Liu, S., Cai, S.-P., Yao, W., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0089046 · Cited by 35
Validation of a sensitive and specific real‐time PCR for detection and quantitation of hepatitis B virus covalently closed circular DNA in plasma of chronic hepatitis B patients
Takkenberg, R. B., Zaaijer, H. L., Molenkamp, R., Menting, S., Terpstra, V., Weegink, C. J., Dijkgraaf, M. G. W., Jansen, P. L. M., Reesink, H. W., & Beld, M. (2009) · Journal of Medical Virology · doi:10.1002/jmv.21477 · Cited by 35
Reverse transcriptase droplet digital PCR vs reverse transcriptase quantitative real‐time PCR for serum HBV RNA quantification
Limothai, U., Chuaypen, N., Poovorawan, K., Chotiyaputta, W., Tanwandee, T., Poovorawan, Y., & Tangkijvanich, P. (2020) · Journal of Medical Virology · doi:10.1002/jmv.25792 · Cited by 39
Correlation of serum hepatitis B surface antigen level with response to entecavir in naïve patients with chronic hepatitis B
Lee, M.-H., Lee, D. M., Kim, S. S., Cheong, J. Y., & Cho, S. W. (2011) · Journal of Medical Virology · doi:10.1002/jmv.22089 · Cited by 35
Covalently closed-circular hepatitis B virus DNA reduction with entecavir or lamivudine
Bowden, S., LOCARNINI, S. A., Chang, T., Chao, Y., Han, K., Gish, R. G., de Man, R. A., Yu, M., Llamoso, C., & Tang, H. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i15.4644 · Cited by 35
Prevention of hepatitis B virus infection: from the past to the future
Orlando, R., Foggia, M., Maraolo, A. E., Mascolo, S., Palmiero, G., Tambaro, O., & Tosone, G. (2015) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-015-2341-x · Cited by 34
Serum hepatitis B virus DNA before liver transplantation correlates with HBV reinfection rate even under successful low-dose hepatitis B immunoglobulin prophylaxis
Yasunaka, T., Takaki, A., Yagi, T., Iwasaki, Y., Sadamori, H., KOIKE, K. A., Hirohata, S., Tatsukawa, M., Kawai, D., Shiraha, H., et al. (2011) · Hepatology International · doi:10.1007/s12072-011-9265-z · Cited by 34
Kinetics of Intrahepatic Covalently Closed Circular DNA and Serum Hepatitis B Surface Antigen During Antiviral Therapy for Chronic Hepatitis B: Lessons From Experimental and Clinical Studies
Zoulim, F., Testoni, B., & Lebossé, F. (2013) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2013.04.010 · Cited by 34
Hepatitis B surface antigen seroconversion is associated with favourable long‐term clinical outcomes during lamivudine treatment in HBeAg‐negative chronic hepatitis B patients
Idılman, R., Cinar, K., Seven, G., Bozkuş, Y., Elhan, A. H., Bozdayi, M. A., Yurdaydın, C., & Bahar, K. (2011) · Journal of Viral Hepatitis · doi:10.1111/j.1365-2893.2011.01542.x · Cited by 34

Authors: Sung, J. J. Y., Wong, M.-L., Bowden, S., Liew, C.-T., Hui, A. Y., Wong, V. W. S., Leung, N. W. Y., Locarnini, S., & Chan, H. L. Y.
Affiliations: Chinese University of Hong Kong (HK)
Victorian Infectious Diseases Reference Laboratory (AU)
Alice Ho Miu Ling Nethersole Hospital (CN)
Corresponding author: Sung, Joseph J.Y.
ORCID: Sung, Joseph J.Y.
Hui, Alex Y.
Wong, Vincent W.S.
Locarnini, Stephen
Chan, Henry L.Y.
Venue: Gastroenterology
Publisher: Elsevier BV
Published: 2005-06
Volume: 128
Issue: 7
Pages: 1890-1897
ISSN: 0016-5085 (ISSN-L)
DOI: 10.1053/j.gastro.2005.03.009
OpenAlex: W1992475294
Cited by: 218
References: 32
Citations by year: 2026: 1 · 2025: 4 · 2024: 1 · 2023: 3 · 2022: 8 · 2021: 4 · 2020: 7 · 2019: 7 · 2018: 3 · 2017: 10 · 2016: 12 · 2015: 12 · 2014: 16 · 2013: 14 · 2012: 12
FWCI: 12.43
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: Gastroenterology (publishedVersion)
PubMed (publishedVersion)
Funders: Chinese University of Hong Kong
Topics: Health Sciences › Medicine › Epidemiology › Hepatitis B Virus Studies
Health Sciences › Medicine › Hepatology › Hepatitis C virus research
Health Sciences › Medicine › Hepatology › Liver physiology and pathology
Keywords: hepatitis B virus, covalently closed circular DNA, chronic hepatitis B, sustained virological response, lamivudine, pegylated interferon, HBeAg-positive, prognostic factors, serum HBV DNA
MeSH terms: Interferon alpha-2, Adult, Antiviral Agents, DNA, Circular, DNA, Viral, Drug Therapy, Combination, Female, Hepatitis B virus, Humans, Liver, Male, Polyethylene Glycols, Predictive Value of Tests, Recombinant Proteins, Sensitivity and Specificity, Polymerase Chain Reaction, Treatment Outcome, Interferon-alpha, Lamivudine, Hepatitis B, Chronic

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Intrahepatic Hepatitis B Virus Covalently Closed Circular DNA Can Be a Predictor of Sustained Response to Therapy

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks